Novotech

Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized pharmaceutical companies. Founded in 1997 and headquartered in Sydney, Australia, the company has grown into a major player in the Asia-Pacific region with expanding global operations following the acquisition of US-based NCGS.

The organization provides comprehensive clinical development services across every phase of drug development, from early strategy through to regulatory approval. Novotech partners with biotechnology companies to accelerate the development of novel therapeutics by offering expert guidance on clinical trial design, regulatory strategy, site selection, patient recruitment, and data management. The company has established strong clinical teams across multiple regions including Australia, New Zealand, Singapore, South Korea, Malaysia, Thailand, and the United States, enabling them to deliver quality CRO services with deep local knowledge and regulatory expertise.

Novotech is known for its collaborative, science-driven approach and has received numerous industry awards recognizing its excellence in clinical research. The company produces thought leadership content including disease reports, white papers, webinars, and podcasts that track trends across therapeutic areas such as oncology, obesity, and idiopathic pulmonary fibrosis. With an award-winning workplace culture and commitment to supporting employee growth, Novotech combines its position as a globally recognized leader in clinical research with a workplace environment that empowers innovation, collaboration, and professional development.